IP Library Granted Patent US 7,078,412
Granted Patent B2
US 7,078,412 · App. 11/116,777 · Granted Jul 18, 2006

Quinuclidine derivatives and medicinal compositions containing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,078,412
App. No.
11/116,777
Granted
Jul 18, 2006
Kind
B2
Abstract

The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.

Claims (10)

1. A compound which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane wherein an anion X − is associated with the positive charge of the nitrogen atom and wherein X − is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

2. The compound according to claim 1 which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1- azoniabicyclo[2.2.2] octane bromide.

3. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.

4. The pharmaceutical composition of claim 3 comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3 -phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide.

5. The pharmaceutical composition according to claim 3 further comprising a β 2 agonist.

6. The pharmaceutical composition according to claim 4 further comprising a β 2 agonist.

7. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of a compound according to claim 1 .

8. The method according to claim 7 comprising administering to the patient an effective amount of 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide.

9. The method according to claim 7 further comprising administering to the patient an effective amount of a β 2 agonists.

10. The method according to claim 8 further comprising administering to the patient an effective amount of a β 2 agonist.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: FERNANDEZ FORNER, MARIA DOLORS; PRAT QUINONES, MARIA; BUIL ALBERO, MARIA ANTONIA
To: ALMIRALL PRODESFARMA, S.A.
Reel/Frame 042416/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: ALMIRALL PRODESFARMA, S.A.
To: ALMIRALL PRODESFARMA AG
Reel/Frame 042416/0819 →
CHANGE OF NAME Recorded Jan 8, 2010
From: LABORATORIOS ALMIRALL, S.A.
To: ALMIRALL, S.A.
Reel/Frame 023750/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2007
From: ALMIRALL AG
To: LABORATORIES ALMIRALL, S.A.
Reel/Frame 019649/0852 →
CHANGE OF NAME Recorded Mar 7, 2007
From: ALMIRALL PRODESFARMA AG
To: ALMIRALL AG
Reel/Frame 018972/0464 →